Psychotropic drug prescribing for children and adolescents is frequently off-label and has increased over time and can be controversial. Psychotropic prescribing in two large UK medium secure units for young people has been studied. A total of 89 patients were included, 64% being aged less than 18 years. A total of 137 of 202 (67.8%) of prescriptions were off-label. The most common reasons for a prescription being off-label were the indication (N = 103) and the patient’s age (N = 41). The main classes of drugs involved were antipsychotics (N = 59), antiepileptics as mood stabilisers (N = 22), anticholinergics and hyoscine (N = 15) and antidepressants (N = 11). Aggression (N = 48) and post-traumatic stress disorder (N = 30) were the most common off-label indications. Some antidepressant prescriptions were contrary to advice of the Committee on Safety of Medicines (CSM). Meta-analyses or randomised controlled trials supported 27% of off-label prescriptions, with lesser quality studies supporting a further 29.2% and expert opinion 38.7%, whereas for 5.1% no evidence could be found. Prescribers tended to over-estimate the level of evidence from clinical trials or extrapolated from findings in adults. They often quoted their own experience rather than expert sources to justify their prescribing practice. It is important that prescribers are fully aware of the quality of experimental data and the risk-benefit ratio when prescribing off-label for young persons. If the evidence base is limited, it is particularly important to provide information about the risks and benefits of the treatment to the patient/relatives. A second opinion may be helpful. Both target symptoms and side effects should be monitored and regularly reviewed.
Anderson, IM, Ferrier, IN, Baldwin, RC ( 2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol22: 343-396.
2.
Baldwin, D., Kosky, N. ( 2007) Off-label prescribing in psychiatric practice. Adv Psychiatr Treat13: 414-422.
3.
Bhatara, V., Feil, M., Hoagwood, K., Vitiello, B., Zima, B. ( 2004) National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord7: 217-226.
4.
Bramble, D. ( 2007) Psychotropic drug prescribing in child and adolescent learning disability psychiatry. J Psychopharmacol21: 486- 491.
5.
Bridge, JA, Iyengar, S., Salary, CB, Barbe, RP, Birmaher, B., Pincus, HA, et al. (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomised controlled trials. JAMA297: 1683-1696.
6.
British Association for Psychopharmacology ( 1997) BAP consensus statement. Child and learning disability psychopharmacology. J Psychopharmacol11: 291-294.
7.
British Medical Association and Royal Pharmaceutical Society of Great Britain (2008a) British National Formulary No. 55. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
8.
British Medical Association and Royal Pharmaceutical Society of Great Britain (2008b) British National Formulary for Children. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
9.
Clark, AF ( 2004) Incidences of new prescribing by British child and adolescent psychiatrists: a prospective study over 12 months. J Psychopharmacol18: 115-120.
10.
Clavenna, A., Rossi, E., Derosa, M., Bonati, M. ( 2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr166: 339-347.
11.
Committee of Safety of Medicines (2004) Safety of selective serotonin reuptake inhibitor antidepressants. 6 December , 1-2.
12.
Cook, A., Spinazzola, J., Ford, J., Lanktree, C., Blaustein, M., Cloitre, M., et al. (2005) Complex trauma in children and adolescents . Psychiatr Ann35: 390-398.
13.
Cooper, WO, Arbogast, PG, Ding, H., Hickson, GB, Fuchs, DC, Ray, WA ( 2006) Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr6: 79-83.
14.
Dean, AJ, McDermott, BM, Marshall, MM ( 2006) Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol16: 273-285.
15.
Doerry, U., Kent, L. ( 2003) Prescribing practices of community child and adolescent psychiatrists. Psychiatr Bull27: 407-410.
16.
Eccles, M., Mason, J. ( 2001) How to develop cost-conscious guidelines. Health Technol Assess5: 8.
17.
Fedorowicz, VJ, Fombonne, E. ( 2005) Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol19: 533-550.
18.
Findling, RL ( 2001) Paediatric psychopharmacology: closing the gap between science and practice. Expert Opin Pharmacother2: 523-525.
19.
Findling, RL, Steiner, H., Weller, EB ( 2005) Use of antipsychotics in children and adolescents . J Clin Psychiatry66(Suppl. 7): 29-40.
20.
General Medical Council (2008) Good practice in prescribing medicines. http://www.gmc-uk.org/guidance/current/library/prescriptions_faqs.asp . [accessed 05.04.09].
21.
Healy, D., Nutt, D. ( 1998) Prescriptions, licence and evidence. Psychiatr Bull22: 680-684.
22.
James, A. ( 2008) Pharmacotherapy and child psychiatry: is there a way forward ? Adv Psychiatr Treat14: 10-16.
23.
Mayes, R., Rafalovitch, A. ( 2007) Suffer the restless children: the evolution of ADHD and paediatric stimulant use, 1900-80. Hist Psychiatry18: 435-457.
24.
McConville, BJ, Sorter, MT ( 2004) Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry65(Suppl. 6): 20-29.
25.
McCracken, JT; on behalf of the Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioural problems. N Engl J Med347: 314-321.
26.
McDougle, CJ, Holmes, JP, Carlson, DC, Pelton, GH, Cohen, DJ, Price, LH ( 1998) A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders . Arch Gen Psychiatry55: 633-641.
27.
Medicines and Healthcare products Regulatory Authority ( 2007) EU Regulations on paediatric medicines. http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesforchildren/index.html . [accessed 05.04.09].
28.
Morgan, S., Taylor, E. ( 2007) Antipsychotic drugs in children with autism. Br Med J334: 1069-1070.
29.
Najjar, F., Welch, C., Grapentine, WL, Sachs, H., Siniscalchi, J., Price, LH ( 2004) Trends in psychotropic drug use in a child psychiatric hospital from 1991-1998. J Child Adolesc Psychopharmacol14: 87-93.
30.
Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., Eerdekens, M. ( 2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behaviour disorders. Am J Psychiatry163: 402-410.
31.
Royal College of Psychiatrists (2007) Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice (College Report CR142). London: Royal College of Psychiatrists.
32.
Schirm, E., Tobi, H., Zito, JM, de Jong-van den Berg, LTW ( 2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics108 (E25).
33.
Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004) Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrica114: 634-641.
34.
SPSS Inc (2006) SPSS for Windows Release 14.0.2. Chicago: SPSS Inc.
35.
Taylor, D., Paton, C., Kerwin, R. ( 2007) The Maudsley Prescribing Guidelines, ninth ed. London: Informa Healthcare.
36.
Thomas, CP, Conrad, P., Casler, R., Goodman, E. ( 2006) Trends in the use of psychotropic medications among adolescents . Psychiatr Serv57: 63-69.
37.
Timimi, S. ( 2008) Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues. Adv Psychiatr Treat14: 3-9.
38.
Whittington, CJ, Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., Boddington, E. ( 2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet363: 1341-1345.
39.
Wong, IC, Murray, ML, Camilleri-Novak, D., Stephens, P. ( 2004) Increased prescribing trends of paediatric psychotropic medications. Arch Dis Child89: 1131-1132.
40.
World Health Organisation (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation.
41.
Yorston, G., Pinney, A. ( 2000) Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics . Psychiatr Bull24: 130-132.
